



## **Delphi Diagnostics Appoints Harry Bushong to Board of Directors**

*Seasoned venture capital leader brings deep expertise in life sciences and healthcare innovation*

**Houston, TX, April 6, 2026** — Delphi Diagnostics today announced the appointment of Harry Bushong to its Board of Directors. A veteran entrepreneur and venture capitalist, Bushong brings extensive experience across healthcare, biotechnology, biopharmaceuticals, materials science, and digital health.

Bushong currently serves as Chief Executive Officer of Convergence Ventures, based in Houston, Texas, where he leads investment strategy and supports the growth of early-stage and development-stage companies. Over the course of his career, he has successfully raised capital for venture funds and investment programs and has played a key role in guiding emerging companies through multiple rounds of financing.

“Harry’s track record of building and scaling innovative life sciences companies makes him an exceptional addition to our Board,” said Winz Casagrande, Chief Executive Officer of Delphi Diagnostics. “His strategic insight and experience in navigating early-stage growth will be invaluable as we continue to advance our mission to help patients, clinicians, and healthcare systems by maximizing disease-free breast cancer survival.”

“I am excited to join the Board of Delphi Diagnostics at such a pivotal time,” said Bushong. “The company’s commitment to innovation in diagnostics and its potential to improve patient outcomes align strongly with my experience and interests. I look forward to supporting the team as they continue to execute on their vision.”

### **About EAI**

Delphi Diagnostics' Endocrine Activity Index® (EAI™) test can provide actionable information for prognosis and prediction of dose-intense taxane-based chemotherapy benefit in stage II-III, HR+ HER2- breast cancer. The EAI measures endocrine activity in a breast tumor and for prognostic use, the Index Score is adjusted for baseline prognosis using molecular subtype genes (RNA4) and clinical factors such as tumor size and regional lymph node involvement. The EAI test has been shown in various studies to be a consistent prognostic indicator for long-term outcomes in stage II-III breast cancer patients, to be independent of other prognostic tests, as well as to be predictive for response to dose-dense chemotherapy.

### **About Delphi Diagnostics**

Delphi Diagnostics Inc. is a Texas-based company focused on advancing clinically valid tests for the prognosis and prediction of breast cancer treatment. Delphi Diagnostics, Inc. holds an exclusive

license from The University of Texas MD Anderson Cancer Center in Houston, TX to commercialize the Endocrine Activity Index, a technology that was developed by the laboratory of Dr. W. Fraser Symmans\*\*. The Endocrine Activity Index (EAI) test measures endocrine activity in stage II-III, HR+HER2-breast cancer. Delphi's vision is to make the EAI test available to breast cancer patients and open new pathways for personalized breast cancer treatment. To learn more, visit [www.delphi-diagnostics.com](http://www.delphi-diagnostics.com).

\*\*Dr. Symmans has a personal financial relationship with Delphi that has been identified as a conflict of interest with this research and is managed by MD Anderson's Conflict of Interest Committee.

**Media Contact:**

Emily Granger

Delphi Diagnostics Inc.

[egranger@delphi-diagnostics.com](mailto:egranger@delphi-diagnostics.com)

508.341.9331